西南医科大学学报2024，Vol.47Issue(6)：471-475,487,6.DOI:10.3969/j.issn.2096-3351.2024.06.003
血管免疫母细胞性T细胞淋巴瘤的诊治进展与展望
Review of advances in diagnosis and treatment of angioimmunoblastic T cell lymphoma
摘要
Abstract
Angioimmunoblastic T-cell lymphoma(AITL)is a highly aggressive subtype of T-cell lymphoma with no standard treatment,resulting in poor survival outcomes for patients.With its high heterogeneity,complex pathogenesis and unmet needs in diag-nosis and treatment,this disease has received considerable attention.Accurate diagnosis and effective treatment are essential to improve patient prognosis.Emerging molecular technologies and flow cytometry are progressively improving the accuracy of early detection of AITL,building on traditional histopathology.Given the limited efficacy of conventional chemotherapy,current research is focused on the development of targeted therapies and immunotherapies.This article reviewed the pathogenesis,diagnostic methods,and treatment strat-egies for AITL and explored future research directions in this field.关键词
血管免疫母细胞性T细胞淋巴瘤/发病机制/基因突变/诊断/治疗策略Key words
Angioimmunoblastic T-cell lymphoma/Pathogenesis/Genetic mutations/Diagnosis/Treatment strategies分类
临床医学引用本文复制引用
徐才刚,王雪梅..血管免疫母细胞性T细胞淋巴瘤的诊治进展与展望[J].西南医科大学学报,2024,47(6):471-475,487,6.基金项目
四川省科技厅重点研发项目(2019YFS0027) （2019YFS0027）
